Ku, MD, highlights emerging therapies in the treatment paradigm for patients with gastric and gastroesophageal junction cancers. In a recent interview with Targeted Oncology, Geoffrey Y. Ku, MD, ...

Inhibrx's INBRX-106 nearly doubles response rate versus Keytruda alone in head and neck cancer trial. See the breakthrough ...

Elevra’s Chief Executive Officer and Managing Director, Mr Lucas Dow, said: “The NAL Expansion PFS confirms a compelling value proposition for Elevra, with a high-return brownfield expansion that ...

Inhibrx CEO Mark Lappe was particularly keen on INBRX-106’s performance in patients with HPV-positive disease and sees a ...

The Real Shift in Camizestrant Approval Is Moving the Trigger to Change Therapy from the Scan to the Blood / Breast Cancer, camizestrant, FDA, ...

Inhibrx Biosciences’ CEO has argued that the 9.6 months of progression-free survival (PFS) demonstrated by its OX40 agonist ...

MAYFAIR GOLD ADVANCES EXPLORATION TARGETS AND PROJECT GEOLOGY AT FENN-GIB. TORONTO, Sept. 8, 2026 /PRNewswire/ -- Mayfair Gold Corp. ( Mayfair, Mayfair Gold, or the Company ) (TSXV: MFG) (NYSE Ameri ...

Australia-based developer Brazilian Rare Earths (BRE) has produced its first rare earth concentrate at its stage one pilot facility in Camacari, located in Brazil's northeastern Bahia state.

Akeso and Summit Therapeutics' ivonescimab has shown further benefit in a first-line non-small cell lung cancer (NSCLC) Phase III study, meeting the key secondary overall survival (OS) endpoint.

FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for adult patients with ESR1-mutated HR+/HER2- ...

Clinicians weigh acalabrutinib vs zanubrutinib for relapsed CLL, focusing on adverse effects, trial data, and where ...

SANOVO met its phase III PFS endpoint with osimertinib plus savolitinib in first-line EGFR-mutated NSCLC with MET ...